OBJECTIVES: The aim of our study was to evaluate the symptomatic and urodynamic changes after 1-5 years of treatment with @entity31503 in @entity1 with @entity1067 . METHODS: Out of 255 @entity1 with lower urinary tract symptoms observed from 1992 to 1997, who completed the International Prostatic Symptom Score (I-PSS) and underwent full urodynamic investigation, 161 were found to be obstructed (Sch  fer classes 2-6). One hundred and two subsequently consented to a second clinical and urodynamic evaluation. Out of these, 46 underwent surgical treatment, 20 were elected for watchful waiting (WW) and 36 received a medical treatment. Twenty out of these, with a mean age of 65 years, a mean prostatic volume of 44 ml (20-70) a median Sch  fer's obstruction class of 3 (range 2-5) were treated with slow release @entity31503 5 mg twice a day. We re-evaluated these 20 @entity1 with a second I-PSS and pressure-flow study after 1-5 years (mean: 2 years) of treatment. The @entity1 in the WW group with comparable baseline characteristics were considered as controls. The Wilcoxon matched-pairs signed rank test and the Kruskal-Wallis test were used for statistical analysis. RESULTS: In the group treated with @entity31503 , no differences were noted for I-PSS (14.9 +/- 6,8; 13.3 +/- 5); maximum flow (124 +/- 6; 14 +/- 6) and projected isometric pressure (105 +/- 36; 105 +/- 26). Statistically significant differences were noted for residual urine (103 +/- 100; 33 +/- 38, p = 0.02); detrusor pressure at maximum flow (64.4 +/- 23; 53 +/- 12, p = 0.04), minimum urethral opening pressure (36.5 +/- 9; 31 +/- 9, p = 0.02), Sch  fer class (2.7 +/- 0.7; 2 +/- 0.8, p = 0.04); urethral resistance algorithm (34.7 +/- 11; 27 +/- 7, p = 0.02). Statistically significant differences between baseline and follow-up were noted for none of the clinical and urodynamic parameters in the WW group. CONCLUSIONS: @entity1 with @entity1876 seem to remain clinically stable and to improve urodynamically when treated with @entity31503 for a long period of time.

Clinical and pressure-flow changes after long-term treatment with XXXX SR.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1067 :: ('MESH:D011470', 'Disease') :: ['benign prostatic hyperplasia'] @entity1876 :: ('MESH:D001748', 'Disease') :: ['bladder outlet obstruction'] @entity31503 :: ('MESH:C047638', 'Chemical') :: ['alfuzosin']
@entity31503 :: (MESH:C047638,Chemical) :: ['alfuzosin']
